Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Chen, Xin ^a   Wakefield, Lalage M ^b   Oppenheim, Joost J ^b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti TGF antibody; Chemoimmunotherapy; Cyclophosphamide

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVATION; CELL ACTIVITY; CELL DEATH; CELL DIFFERENTIATION; CELL INFILTRATION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; MYELOID DERIVED SUPRESSOR CELL; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PROCESS OPTIMIZATION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TH17 CELL;

EID: 84902590233     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28247     Document Type: Note

References (10)

1. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 2014; 588:368-76; PMID:24161671; http://dx.doi.org/10.1016/j. febslet.2013.10.015
2. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27C:1-7; PMID:24413387; http://dx.doi. org/10.1016/j.coi.2013.12.005
3. Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ. Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer. PLoS One 2014; 9:e85398; PMID:24416401; http://dx.doi.org/10.1371/journal. pone.0085398
4. Fox FE, Ford HC, Douglas R, Cherian S, Nowell PC. Evidence that TGF-beta can inhibit human T-lymphocyte proliferation through paracrine and autocrine mechanisms. Cell Immunol 1993; 150:45-58; PMID:8393732; http:
5. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 2009; 58:1219-28; PMID:19052741; http://dx.doi.org/10.1007/s00262-008-0628-9
6. Zhou Q, Hu Y, Howard OM, Oppenheim JJ, Chen X. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo. Cytokine 2014; 65:56-64; PMID:24080164; http://dx.doi.org/10.1016/j. cyto.2013.09.008
7. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011; 35:972-85; PMID:22177921; http://dx.doi. org/10.1016/j.immuni.2011.09.019
8. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971-6; PMID:24264990; http:// dx.doi.org/10.1126/science.1240537
9. Chen G, Emens LA. Chemoimmunotherapy:reengineering tumor immunity. Cancer Immunol Immunother 2013; 62:203-16; PMID:23389507; http://dx.doi.org/10.1007/s00262-012-1388-0
10. Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 2013; 13:788-99; PMID:24132110; http:// dx.doi.org/10.1038/nrc3603